These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 15231512

  • 1. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL, Barerra P.
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [Abstract] [Full Text] [Related]

  • 2. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis.
    Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW.
    Ann Rheum Dis; 2005 Aug; 64(8):1195-8. PubMed ID: 15731289
    [Abstract] [Full Text] [Related]

  • 3. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
    Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, van der Meer JW, van Riel PL, Stalenhoef AF, Barrera P.
    Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
    [Abstract] [Full Text] [Related]

  • 4. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
    Dahlqvist SR, Engstrand S, Berglin E, Johnson O.
    Scand J Rheumatol; 2006 Nov; 35(2):107-11. PubMed ID: 16641043
    [Abstract] [Full Text] [Related]

  • 5. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT.
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [Abstract] [Full Text] [Related]

  • 6. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF.
    Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
    [Abstract] [Full Text] [Related]

  • 7. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 8. Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3.
    Sarzi-Puttini P, Atzeni F, Schölmerich J, Cutolo M, Straub RH.
    Ann Rheum Dis; 2006 Mar; 65(3):301-5. PubMed ID: 16079165
    [Abstract] [Full Text] [Related]

  • 9. Anti-tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases androstenedione relative to cortisol.
    Straub RH, Sarzi-Puttini P, Atzeni F, Buttgereit F, Carrabba M, Cutolo M.
    Ann Rheum Dis; 2005 Sep; 64(9):1353-6. PubMed ID: 15708882
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
    Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M.
    Ann N Y Acad Sci; 2006 Jun; 1069():414-9. PubMed ID: 16855168
    [Abstract] [Full Text] [Related]

  • 12. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis.
    Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D.
    Clin Chim Acta; 2006 Mar; 365(1-2):143-8. PubMed ID: 16176811
    [Abstract] [Full Text] [Related]

  • 13. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study.
    Peters MJ, Welsh P, McInnes IB, Wolbink G, Dijkmans BA, Sattar N, Nurmohamed MT.
    Ann Rheum Dis; 2010 Jul; 69(7):1281-5. PubMed ID: 19934107
    [Abstract] [Full Text] [Related]

  • 14. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.
    Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K.
    Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):1004-7. PubMed ID: 12635469
    [Abstract] [Full Text] [Related]

  • 15. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA.
    J Rheumatol; 2006 May 30; 33(5):921-3. PubMed ID: 16541480
    [Abstract] [Full Text] [Related]

  • 16. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT.
    J Rheumatol; 2008 Oct 30; 35(10):1972-7. PubMed ID: 18785316
    [Abstract] [Full Text] [Related]

  • 17. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy.
    Straub RH, Härle P, Atzeni F, Weidler C, Cutolo M, Sarzi-Puttini P.
    J Rheumatol; 2005 Jul 30; 32(7):1253-8. PubMed ID: 15996060
    [Abstract] [Full Text] [Related]

  • 18. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis.
    Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, Dijkmans BA, Twisk JW, de Koning MH, van de Stadt RJ, Nurmohamed MT.
    Ann Rheum Dis; 2007 Jul 30; 66(7):958-61. PubMed ID: 17314120
    [Abstract] [Full Text] [Related]

  • 19. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
    Van Doornum S, McColl G, Wicks IP.
    Rheumatology (Oxford); 2005 Nov 30; 44(11):1428-32. PubMed ID: 16076882
    [Abstract] [Full Text] [Related]

  • 20. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C, Ribeiro AC, Fabri GM, Calich AL, Carvalho J, Silva CA, Viana VS, Bonfá E, Siqueira JT.
    J Clin Rheumatol; 2012 Jun 30; 18(4):180-4. PubMed ID: 22647860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.